How does invasive mechanical ventilation effect the intensive care outcomes during prepandemic and SarsCoV2 pandemic?
Nalan Adıgüzel,Sinem Gungor,Zuhal Karakurt,Bariş Yilmaz,Özlem Yazıcıoğlu Moçin,Eylem Tunçay,Inşa Gül Ekiz Işcanlı,Feyza Kargın,Nezihe Çiftaslan Gökşenoğlu,Gul Erdal Donmez,Huriye Berk Takır,Meltem Ağca,Betül Çakmak,Nazli Deniz Tunc,Yeşim Karadeniz,Fırat Saydın,Buse Nur ERTAM,Gokay Gungor
DOI: https://doi.org/10.1016/j.jcrc.2024.154716
IF: 4.298
2024-04-01
Journal of Critical Care
Abstract:Introduction and aim Intubated ICU patients with acute respiratory failure (ARF) who need invasive mechanical ventilation (IMV) had a higher mortality rate. IMV mortality increased in Covid-19 patients during the SarsCoV2 pandemic. We evaluated overall mortality in IMV patients before and throughout the 3-year SarsCoV2 pandemic. Patients and methods A retrospective, observational, cross-sectional study was conducted in a level 3 ICU of a teaching hospital between 2017 and 2022. The study period was defined as the pre-pandemic period 2017–2019 and the SarsCov2 Pandemic period 2020–2022. During the study period, every patient admitted to the ICU and received IMV was included in the study. Demographic characteristics, comorbidities, causes of ARF, ICU severity score, ICU length of stay and ICU mortality were recorded. Patients were grouped according to pre-pandemic and pandemic period and their mortality rates were compared. Multiple logistic regression test was used for mortality risk analysis after mortality subgroup comparison. Results The number of patients (%) who received IMV before and during the pandemic were 1797 (46%) and 2256 patients (37%), respectively ( p < 0.001). In the mortality comparison of pre-pandemic and pandemic years, the number of patients who received IMV in 2017, 2018, 2019 were n = 639, n = 600, n = 558 and mortality rates were 43% ( n = 272), 42% ( n = 255), 41% ( n = 228), respectively, while mortality rates were 46% ( n = 253), 53% ( n = 414), 64% ( n = 594) in 2020, 2021, 2022 (p < 0.001). General characteristics, comorbidities and ICU data of all patients, pre-pandemic – pandemic and survivor - non survivor patients are shown in Table 1. Hypertension, DM, ischemic heart disease (IHD) were significantly higher in pandemic ( p < 0.05), COPD and malignancy were significantly higher in pre-pandemic (p < 0.05). The rate of patients who received only IMV was significantly higher during the pandemic and in nonsurvivors ( p < 0.001). Pneumonia, Covid-19, IHD, malignancy were significantly higher in nonsurvivors; COPD was significantly lower in nonsurvivors (p < 0.05). Odds ratios (CI 95% lower-upper limit) of significant predictors for mortality were as follows: Pandemic period 1.64(1.42–1.90), over 85 years 1.41(1. 14–1.75), ICU stay of 7 days or more 1.25(1.09–1.43), APACHE II score over 25 or more 2.14(1.86–2.47), Covid-19 1.72(1.37–2. 15), pneumonia 1.42(1.18–1.70), malignancy 2.99(2.50–3.58), ICH 1.43(1.20–1.70), sepsis 0.75(0.64–0.89), COPD 0.78(0.67–0.91). Conclusion IMV application was significantly less in the pandemic, Covid-19 may have been avoided because it increases the risk of mortality. In patients with advanced age, high APACHE II scores, pneumonia, Covid-19, malignancy and IHD may predictors of mortality, whereas sepsis and COPD co-morbidity may decrease mortality in patients receiving IMV.
critical care medicine